Sabatino Ventura

Sabatino Ventura

Auto-generated profile, based on publicly available information

Sabatino Ventura

Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Australia

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2011 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
SVS Ventura
S Ventura
VOVl Oliver
Vl Oliver
CWCw White
Cw White
JXJh Xie
Jh Xie
JHJm Haynes
Jm Haynes
BEBetty Exintaris
Betty Exintaris

2 December 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
CWCarl W. White
Carl W. White
YCYan-Ting Choong
Yan-Ting Choong
JSJennifer L. Short
Jennifer L. Short
BEBetty Exintaris
Betty Exintaris
DMDaniel T. Malone
Daniel T. Malone
SVSabatino Ventura
Sabatino Ventura
Therapeutic targets for male contraception are associated with numerous problems due to their focus on disrupting spermatogenesis or hormonal mechanisms to produce dysfunctional sperm. Here we describe the dual genetic deletion of α1A-adrenergic G protein-coupled receptors (adrenoceptors) and P2X1-purinoceptor ligand gated ion channels in male mice, thereby blocking sympathetically mediated sperm transport through the vas deferens during the emission phase of ejaculation. This modification produced 100% infertility without effects on sexual behavior or function. Sperm taken from the cauda epididymides of double knockout mice were microscopically normal and motile. Furthermore, double knockout sperm were capable of producing normal offspring following intracytoplasmic sperm injection into wild-type ova and implantation of the fertilized eggs into foster mothers. Blood pressure and baroreflex function was reduced in double knockout mice, but no more than single knockout of α1A-adrenoceptors alone. These results suggest that this autonomic method of male contraception appears free of major physiological and behavioral side effects. In addition, they provide conclusive proof of concept that pharmacological antagonism of the P2X1-purinoceptor and α1A-adrenoceptor provides a safe and effective therapeutic target for a nonhormonal, readily reversible male contraceptive. Significance The search for a viable male contraceptive target has been a medical challenge for many years. Most strategies have focused on hormonal or germ-line strategies to produce dysfunctional sperm that are incapable of fertilization. The problem with such approaches is that they have intolerable side effects such as affecting male sexual activity or causing long-term irreversible effects on fertility. In addition, some strategies may transmit detrimental changes to future offspring. This manuscript describes a male contraceptive target within the autonomic nervous system, which would not affect the long-term viability of sperm nor the sexual or general health of males. In addition, due to the nature of the target, the contraceptive has the potential to be orally administered.

1 July 2013 in Organogenesis
Verified
Journal Article
Open access
CWCarl W White
Carl W White
JXJin Han Xie
Jin Han Xie
SVSabatino Ventura
Sabatino Ventura
The adult prostate gland grows and develops under hormonal control while its physiological functions are controlled by the autonomic nervous system. The prostate gland receives sympathetic input vi...

11 July 2022 in Purinergic Signalling
Verified
Journal Article
Open access
PDF file
FBFelix M. Bennetts
Felix M. Bennetts
JMJesse I. Mobbs
Jesse I. Mobbs
SVSabatino Ventura
Sabatino Ventura
DTDavid Thal
David Thal
Within the family of purinergic receptors, the P2X1 receptor is a ligand-gated ion channel that plays a role in urogenital, immune and cardiovascular function. Specifically, the P2X1 receptor has been implicated in controlling smooth muscle contractions of the vas deferens and therefore has emerged as an exciting drug target for male contraception. In addition, the P2X1 receptor contributes to smooth muscle contractions of the bladder and is a target to treat bladder dysfunction. Finally, platelets and neutrophils have populations of P2X1 receptors that could be targeted for thrombosis and inflammatory conditions. Drugs that specifically target the P2X1 receptor have been challenging to develop, and only recently have small molecule antagonists of the P2X1 receptor been available. However, these ligands need further biological validation for appropriate selectivity and drug-like properties before they will be suitable for use in preclinical models of disease. Although the atomic structure of the P2X1 receptor has yet to be determined, the recent discovery of several other P2X receptor structures and improvements in the field of structural biology suggests that this is now a distinct possibility. Such efforts may significantly improve drug discovery efforts at the P2X1 receptor.

1 January 2010 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
YXYuanhao Xu
Yuanhao Xu
SVSabatino Ventura
Sabatino Ventura

1 March 2014 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
TCThiam Chua
Thiam Chua
NENicole T. Eise
Nicole T. Eise
JSJamie S. Simpson
Jamie S. Simpson
SVSabatino Ventura
Sabatino Ventura